Pruritus Therapeutics Market Expected to Reach $11.2 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Pruritus Therapeutics Market," The pruritus therapeutics market was valued at $7.9 billion in 2021, and is estimated to reach $11.2 billion by 2031, growing at a CAGR of 3.6% from 2022 to 2031.

The most prevalent sign of skin disease, pruritus (itching), is best described as a sensation that makes people want to scratch.  It may also be the primary symptom of psychiatric and systemic illnesses. When an underlying cause cannot be diagnosed, managing pruritus can be challenging. Creation of efficient treatment solutions for pruritus has proven to be particularly challenging, owing to poorly known pathogenesis. So far, there is no treatment for pruritus that is accepted everywhere. Instead, a customized strategy to pruritus control is used. However, recent developments in diagnosis of pathophysiology of pruritus have shown opportunities to explore causes of this disease and provided opportunities for further developments of therapeutics.
High demand for over-the-counter topical treatments, new product releases, and a solid pipeline are the pruritus therapeutics market trends. However, an insufficient knowledge about the underlying causes of pruritus is a restraint that prevents the pruritus therapeutics market growth. Moreover, patent expiration of several pruritus treatments is the prospect that may provide a favorable environment for the market expansion.
Despite conventional pharmacotherapies having well-established antipruritic characteristics, these treatments frequently fall short of providing enough relief for affected individuals. As a result of expanding pruritic research field, additional experimental and clinical data have emerged, consistently enhancing the possibility for introducing new approaches to treatment. 
New therapeutic modalities have been created and are expected to soon be added to the group of antipruritic medications that dermatologists employ on a daily basis.
The global market for pruritus therapies is segmented on the basis of drug type, disease, distribution channel and region. On the basis of drug type, the pruritus therapeutics market size is segmented into corticosteroids, antihistamines, local anesthetics, immunosuppressants, and others. The corticosteroids segment generated highest revenue in 2021, owing to high prevalence rate throughout the world and resulting high demand for corticosteroids as treatment to cure pruritus. The corticosteroid segment was the largest segment in 2021, and is expected to grow at a CAGR of 4.4% during the forecast period. Furthermore, the others segment is expected to grow at a CAGR of 4.0% during the forecast period.
A more significant underlying cause is typically indicated when pruritus persists for a longer time. On the basis of disease type, the global pruritus therapeutics market is divided into atopic dermatitis, allergic contact dermatitis, urticaria, and others. The atopic dermatitis segment is expected to grow at a CAGR of 3.2% during the forecast period. A heightened inflammatory response to a variety of potential irritants, such as dust, environmental pollutants, animals, certain foods, can cause eczema, which is also known as atopic dermatitis. The causes and prevalence of large number of the factors that lead to generation of the disease propels growth of the segment.
By distribution channels, the pruritus therapeutics market share market is divided into hospital pharmacies, drug store & retail pharmacies, and online providers. The drug stores & retail pharmacies segment is further divided, on basis of route of administration, into oral route, parenteral route, and topical route.
This segment held the largest share of the market, owing to easy accessibility, high availability, and cost-effectiveness of services they provide. However, the online providers segment is expected to grow, owing to digitalization and convenient services at a CAGR of 5.5% during the forecast period.
Region wise, North America acquired a major share of the market in the year 2021, owing to presence of key players, rise in government initiatives, well-developed healthcare infrastructure, and increase in prevalence of skin related health issues. However, Asia-Pacific is expected to witness highest growth during the forecast period. Increase in R&D investments, growth in awareness of newer therapies, and rise in consumer preferences toward OTC products are prime factors that supplement growth of the Asia-Pacific market. However, insufficient knowledge about pathogenesis and treatment hinders the pruritus therapeutics industry.

 Key findings of the study
•    On the basis of drug type, the corticosteroids segment held the largest market share in 2021, and is expected to remain dominant during the forecast period. 
•    On the basis of disease type, the atopic dermatitis segment held the largest market share in 2021, and the others segment is expected to be the fastest growing segment during the forecast period.
•    On the basis of distribution channel, the drug store and retail pharmacies segment held largest market share in 2021, whereas the online providers segment is expected to be the fastest growing segment during the forecast period.
•    Region wise, North America held the largest market segment in 2021, and Asia-Pacific is expected to experience growth at the highest rate during the forecast period.